Please login to the form below

Not currently logged in
Email:
Password:

Cubist picks Robert Perez as its new CEO

He replaces Michael Bonney who will continue as chair

Cubist, Robert PerezAntibiotic specialist Cubist Pharmaceuticals has announced that CEO Michael Bonney will step down from his position at the end of this year to be replaced by Robert Perez (pictured right).

Bonney, who will take over as chair of the company's board of directors, has led Cubist since 2003 having joined the company a year earlier as chief operating officer. He previously spent six years at Biogen Idec in various positions.

With Bonney as CEO Cubist has emerged as one of the leading players in antibiotic research, a field that has been neglected by larger pharma companies but is now a growing area as the world recognises the growing threat of antimicrobial resistance.

Cubist's ambitions have been seen with a number of drug launches as well as its recent expansion into Europe with a new office in Zurich.

"Under Mike Bonney's leadership, Cubist made the extraordinarily rare transition from struggling startup to global biotechnology leader with outstanding future growth potential," said Kenneth Bate, chair of the board of directors. Bate will become lead independent director when Bonney becomes chair.

This growth will now be lead by Perez, who knows Cubist well having spent 11 years at the company. He has been in his current position of chief operating officer since 2007 and was also named president in 2012.

He said: “I am confident that we will drive excellence in the research, development and commercialisation of life-saving therapies that will benefit physicians and patients around the world."

Like Bonney, Perez also spent time at Biogen Idec, serving as VP of the company's central nervous system operations in the US. He also worked at Zeneca prior to the company's merger with Astra to become AstraZeneca.

24th October 2014

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...